| HOME >> MEDICINE >> TECHNOLOGY |
-(4,068)190,560(4,006)Restructuring costs
26,986-26,986-Total operating expenses
81,21967,457329,434113,406Gain on sale of product rights and other
-146-5,921Operating (loss) income
17,80724,148(120,755)67,484Interest income
382273805601Interest expense
(150)(918)(301)(1,826)Income (loss) from continuing operations before provision
for income taxes
18,03923,503(120,251)66,259Provision (benefit) for income taxes
8,8595,468(20,587)21,798Income (loss) from continuing operations
9,18018,035(99,664)44,461Discontinued operations:Provision (benefit) for income taxes
127(360)253(232)(Loss) income from discontinued operations
(127)360(253)232Net income (loss)
$9,053$18,395($99,917)$44,693Basic earnings (loss) per share of common stock:Income (loss) from continuing operations
$0.26$0.53($2.79)$1.31(Loss) income from discontinued operations
(0.01)0.01(0.01)0.01Net income (loss)
$0.25$0.54($2.80)$1.32Diluted earnings (loss) per share of common stock:Income (loss) from continuing operations
$0.25$0.51($2.79)$1.26(Loss) income from discontinued operations
(0.00)0.01(0.01)0.01Net income (loss)
$0.25$0.52($2.80)$1.27Weighted average number of common shares outstanding: Basic
35,98334,11235,74234,021 Diluted
36,70835,47535,74235,273PAR PHARMACEUTICAL COMPANIES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Share Data)(Unaudited)June 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents$307,011$218,674Available for sale marketable debt securities38,65227,866Accounts receivable, net 122,63095,705Inventories75,35372,580Prepaid expenses and other current assets14,33817,660Deferred income tax assets30,00926,037Income taxes receivable63,32818,605Total current assets651,321477,127Property, plant and equipment, net71,11771,980Intangible asse
'/>"/>
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2010 PR Newswire. All rights reserved |